Sanofi SA (SAN) PT Set at €88.00 by Citigroup Inc.
SAN has been the topic of a number of other reports. Credit Suisse Group set a €95.00 ($111.76) price target on Sanofi SA and gave the stock a buy rating in a research note on Tuesday, July 4th. HSBC Holdings plc set a €81.00 ($95.29) price target on Sanofi SA and gave the stock a neutral rating in a research note on Wednesday, August 30th. J P Morgan Chase & Co set a €85.00 ($100.00) price target on Sanofi SA and gave the stock a neutral rating in a research note on Thursday, September 14th. Jefferies Group LLC set a €86.00 ($101.18) price target on Sanofi SA and gave the stock a neutral rating in a research note on Monday, September 18th. Finally, Kepler Capital Markets set a €90.00 ($105.88) price target on Sanofi SA and gave the stock a buy rating in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of €87.88 ($103.39).
Shares of Sanofi SA (EPA:SAN) opened at 86.05 on Friday. The company has a market cap of €108.06 billion and a PE ratio of 12.00. Sanofi SA has a 12 month low of €24.55 and a 12 month high of €86.39. The stock has a 50 day moving average of €26.11 and a 200-day moving average of €26.01.
TRADEMARK VIOLATION NOTICE: “Sanofi SA (SAN) PT Set at €88.00 by Citigroup Inc.” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/10/sanofi-sa-san-pt-set-at-88-00-by-citigroup-inc.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.